Answers are grounded in this paper and cite their sources.
Initial screening identifies romidepsin with the highest therapeutic index in osteosarcoma models, suggesting efficacy.
Romidepsin has the largest overall therapeutic index of all 13 hits from the initial screen. Data represent dose–response experiments for top 13 hits from initial screen. Ratios of TD₅₀/sarcosphere (Sarco) ED₅₀ reflect therapeutic indices with NHOst and non-transformed human SAEC. White on the color scale is set at the median of the overall row means, shown in the first column. TD₅₀s, doses that reduce metabolic activity of NHOst and SAEC by 50%, are shown in Supplementary Figs. S5A and S6A. The TD₅₀/ED₅₀ ratios are shown in Supplementary Figs. S5B–S5D and S6B–S6D. TD₅₀s were determined in N = 3 independent dose–response experiments with each drug. Each experiment included at least three culture wells per group. ED₅₀s, doses that reduce metabolic activity of 143B, LM7, or MG63.3-GFP sarcospheres by 50%, are shown in Supplementary Fig. S1B–S1D and Supplementary Table S3.
No takes yet. Share an insight, caveat, or question.
Seiden et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: